https://ntp.niehs.nih.gov/go/28754

Transgenic model evaluation II (Benzene): Target Organs and Levels of Evidence for GMM-08

GMM-08 Toxicology and Carcinogenesis Study of Benzene (CASRN 71-43-2) in Genetically Modified Haploinsufficient p16Ink4a/p19Arf Mice (Gavage Study)

Chemical (Study Title)
CASRN 		Peer Review Date Route/Exposure Levels Study Laboratory
Transgenic model evaluation II (Benzene)
71-43-2 		08/28/2006 Gavage
0, 25, 50, 100, or 200 mg/kg		 Battelle Columbus Laboratory

Levels of evidence information for the Carcinogenesis and Genetic Toxicology Studies of Benzene in Haploinsufficient p16Ink4a/p19Arf Mice (27 Weeks)
  Male Haploinsufficient p16Ink4a/p19Arf Mice Female Haploinsufficient p16Ink4a/p19Arf Mice
  27 Week 27 Week
Levels of Evidence Clear Evidence No Evidence
Neoplastic Lesions
  • Malignant lymphoma: 0/15, 0/15, 0/15, 0/15, 5/15
 None
Non-Neoplastic Lesions
  • Bone marrow: atrophy; hemosiderin pigmentation
  • Spleen: hematopoietic cell proliferation; lymphoid follicle atrophy
  • Thymus: atrophy
  • Lymph node (mandibular): atrophy
  • Lymph node (mediastinal): atrophy
  • Lymph node (mesenteric): atrophy
  • Skin: pigmentation
  • Lymph node (mesenteric): atrophy
  • Skin: pigmentation